Liraglutide
Also known as Victoza · Saxenda · GLP-1 analog
Once-daily GLP-1 receptor agonist with extensive clinical data for diabetes and obesity care.
Evidence visual
Liraglutide evidence and risk matrix
intermediate researcher fit
Evidence
Tier A
Risk
medium
Regulatory
rx approved
WADA
none
FDA
unknown
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Liraglutide is a daily GLP-1 receptor agonist used for type 2 diabetes and obesity. Human evidence is strong, though weight-loss efficacy is typically below semaglutide and tirzepatide. It remains clinically established, but as with other GLP-1 therapies, off-label research sourcing should not be treated as interchangeable with regulated pharmacy product.
Decision path
Where Liraglutide fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Liraglutide belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
GLP-1 receptor agonist that improves satiety and glucose-dependent insulin secretion while slowing gastric emptying.
subcutaneous
Approved human use: 1.2 mg to 1.8 mg daily for diabetes; 3 mg daily for obesity.
Moderate weight loss, improved satiety, and HbA1c reduction in clinical populations.
Metabolic and appetite effects begin within days to weeks; body-weight effects build over months.
Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history and pregnancy.
GI effects are common, especially nausea, vomiting, constipation, and diarrhea. Pancreatitis and gallbladder events remain class concerns.
Same class cautions as other GLP-1 agents: hypoglycemia risk rises with insulin or sulfonylureas, and gastric emptying delay can affect oral medications.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Age, sex, and monitoring
Life-stage fit
Adult metabolic-health use case with the strongest fit when evidence and regulatory clarity matter more than novelty.
Best fit age ranges: 35-44, 45-54, 55-64
Sex-specific note
Broad adult metabolic-use case with a stronger real-world evidence base than most wellness-market peptides.
female
Avoid in pregnancy or active conception planning unless a clinician specifically directs otherwise.
Monitoring burden
mediumRequires follow-up around metabolic response, GI tolerance, and adherence because of daily dosing.
Baseline labs and checks
CMP, fasting glucose or HbA1c, lipids, weight baseline
Follow-up cadence
Early review in the first month, then periodic follow-up every few months.
Red flags
- persistent nausea or vomiting
- gallbladder symptoms
- pancreatitis-type abdominal pain
Known Interactions
Two GLP-1 agonists in the same stack creates redundant mechanism and higher side-effect burden.
Dual incretin and GLP-1-only agonists should not be stacked in consumer protocols.
Do not layer a daily GLP-1 agonist with an investigational triple-agonist compound.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Liraglutide.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.